Search Tag: HCC

2025 25 Feb

  Hepatocellular carcinoma (HCC) presents significant challenges in clinical management due to its high recurrence rates and variable prognosis. Key pathologic features, including microvascular invasion (MVI), poorly differentiated pathologic grade (poor PG) and satellite nodules (SNs), contribute to tumour progression and treatment resistance....Read more

2025 24 Feb

  Liver cancer, particularly hepatocellular carcinoma (HCC), remains one of the leading causes of cancer-related mortality worldwide. Despite advancements in therapeutic options, the variability in patient responses highlights a significant challenge in personalising treatment. Understanding this heterogeneity is crucial for improving outcomes....Read more

2025 14 Jan

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a significant cause of cancer-related mortality globally. Early-stage HCC offers better treatment prospects compared to advanced cases, yet predicting tumour growth rates remains a major clinical challenge. Tumour volume doubling time (TVDT) can vary significantly among individual...Read more

2024 25 Nov

  Hepatocellular carcinoma (HCC) remains a significant global health challenge, ranking among the leading causes of cancer-related mortality. Despite advances in treatments, including surgery, systemic therapies and immunotherapies, survival rates for HCC patients remain low due to its aggressive nature and high recurrence rates. A major factor...Read more